Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency in its Phase 4 clinical trial of Panzytrat® 25,000. Results show that patients taking Panzytrat had better control over their steatorrhea, or fecal fat content. The study was designed to…
News
After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives…
A number of factors influence the health-related quality of life of patients with cystic fibrosis. A new study in the Italian Journal of Pediatrics written by a collaboration of researchers…
Following the recent success of a phase 3b clinical trial for Aztreonam in cystic fibrosis (CF) patients with Burkholderia infections, Gilead Sciences, Inc., a research-based biopharmaceutical company engaged in CF drug discovery and development, completed another phase 3 clinical trial to evaluate the safety of inhalable Aztreonam (AZLI)…
Vertex Pharmaceuticals‘ two-part proof-of-concept study evaluating ivacaftor (under the name KALYDECO) in 24 cystic fibrosis patients shows data consistent with previous preclinical observations. An eight-week open-label period resulted in improved lung function in patients, initiating plans for a future Phase 3 trial. Each of the 24…
A group of thirteen scientists at the University of North Carolina School of Medicine may know why certain cystic fibrosis treatments improve lung function. Their answer: mucins, the proteins within mucus. “Our finding suggests that diluting the concentration of mucins in cystic fibrosis mucus is a key to better…
In some ways, it’s both the best of times and the worst of times for persons afflicted with certain serious disease conditions, such as cystic fibrosis. On the one hand, there have been encouraging and potentially life-changing breakthroughs in terms of therapy options. On the other, these new drugs can…
People with cystic fibrosis can be prone to developing diabetes. However, only recently have researchers learned that the onset of diabetes occurs due to a mutation in a molecular mechanism that increases the risk of developing the disease. As a result, researchers from Lund University in Sweden and Karolinska…
Canada’s CTV News reported late last week that the province of Alberta’s health minister has successfully negotiated a tentative deal that will allow Canadian provinces to cover the cost to their provincial pharmacare plans of the multiple sclerosis (MS) drug Kalydeco, used for treatment of cystic fibrosis (CF)…
A recent study led by GBI Research entitled “Cystic Fibrosis Therapeutics in Major Developed Markets 2019 – CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth,” notes that the Cystic Fibrosis market will grow from $695.6 million in 2012 to near a $ 4.5 billion in 2019 in…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.